# Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy

> **NCT07633236** · PHASE3 · RECRUITING · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 100 (estimated)

## Conditions studied

- Oncology Patients Receiving Chemotherapy
- Cachexia-Anorexia Syndrome
- Oncology

## Interventions

- **DRUG:** OLANZapine 2.5 MG

## Key facts

- **NCT ID:** NCT07633236
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-28
- **Primary completion:** 2026-12-28
- **Final completion:** 2027-05-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633236, "Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*